期刊文献+

依立替康化疗后出现急性出血坏死性肠炎一例 被引量:2

原文传递
导出
摘要 患者,女,49岁,诊断"宫颈癌(Ⅱa2)"明确后行"依立替康240 mg"静脉滴注化学药物治疗.化疗疗程结束后第4天开始腹泻,黄水样便,3~9次/d,并伴有腹痛、腹胀,呈阵发性绞痛,自服蒙脱石散10余天不缓解,考虑为依立替康化疗后出现的迟发性腹泻.既往有哮喘病史.全腹CT检查示部分空肠、回肠及结肠肠管积气,其内见较大液气平且呈阶梯状排列,高位肠梗阻,梗阻部位位于小肠.予禁饮食、胃肠减压、抗感染、补液及生长抑素静脉泵入治疗,患者出现全身中毒症状并持续加重,排血便,有腥臭味,后出现DIC症状,考虑为亚急性DIC.复查全腹CT示小肠高位梗阻,较前片加重,腹腔积液,腹壁软组织水肿并积液,较前片加重(图1).
出处 《中华普通外科杂志》 CSCD 北大核心 2013年第10期791-791,共1页 Chinese Journal of General Surgery
  • 相关文献

参考文献3

二级参考文献56

  • 1张怡,李中东.伊立替康的不良反应及处理[J].中国药物警戒,2006,3(5):271-273. 被引量:12
  • 2邓海燕,贾立群,潘琳,于莉莉,李学,郭艳茹.生姜泻心汤预防伊立替康所致迟发性腹泻的实验研究[J].中日友好医院学报,2006,20(6):344-347. 被引量:23
  • 3王琳,陈映霞,方蓉,秦叔逵,秋雨.伊立替康所致延迟性腹泻的治疗和预防[J].中国处方药,2007,6(8):67-69. 被引量:15
  • 4Ramesh M,Ahlawat P,Srinivas NR.Irinotecan and its active metabolite,SN-38:review of bioanalytical methods and recent update from clinical pharmacology perspectives[J].Biomed Chromatogr,2010,24(1):104-123.
  • 5Stringer AM,Gibson RJ,Bowen JM,et al.Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile[J].Int J Exp Pathol,2009,90(5):489-499.
  • 6Maroun JA,Anthony LB,Blais N,et al.Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer:a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea[J].Curr Oncol,2007,14(1):13-20.
  • 7Benson AB 3rd,Ajani JA,Catalano RB,et al.Recommended guidelines for the treatment of cancer treatment-induced diarrhea[J].J Clin Oncol,2004,22(14):2918-2926.
  • 8Brandi G,Dabard J,Raibaud P,et al.Intestinal microflora and digestive toxicity of irinotecan in mice[J].Clin Cancer Res,2006,12(4):1299-1307.
  • 9Melo ML,Brito GA,Soares RC,et al.Role of cytokines (TNF-alpha,IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice:effect of pentoxifylline and thalidomide[J].Cancer Chemother Pharmacol,2008,61(5):775-784.
  • 10Akinobu K,Kado S,Kaneda N,et al.Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed onset diarrhea in rats[J].Cancer Chemother Pharmacol,2000,46(3):211-220.

共引文献33

同被引文献16

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部